Clinical Trials Browser

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma in Situ

Breast Neoplasms

Breast Neoplasms

Breast Neoplasm Female

Breast Carcinoma In Situ

Anatomic Stage I Breast Cancer AJCC v8

Anatomic Stage I Breast Cancer AJCC v8

Advanced Breast Cancer

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

Breast Neoplasms

Breast Neoplasms, Depression

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Pain, Postoperative

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Carcinoma In Situ

Breast Neoplasms

Breast Cancer Lymphedema

Breast Neoplasms, Neoplasm Metastasis, Disease Progression

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Cancer Female

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Hand-Foot Syndrome

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Clinical Trials

TORCHLIGHT

DEBRA

MAPAM-01

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

ADELA

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

OFSET

HEAL-ABC

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

POWER

LOLIPOP

BCTOP-T-M01

OPTIMA-YOUNG

PLANET

STEREO-SEIN

CRYSTAL

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

MNEMOSYNE

TSARINE

NoLEEta

VITACAL

LoTam

MECCA

Does Immediate Lymphatic Reconstruction Decrease the Risk of Lymphedema After Axillary Lymph Node Dissection

CAPIcorn

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

POWER II

A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction

PATINA

pec's

DISCORDANT

POLARIS

OLIGAMI

A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer

PALLAS

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome

OFOBA

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Neo-NAUTILUS

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

IARA

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection